Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ARUK 2022 | Next steps for research into the NLRP3 inflammasome in dementia

Sarah Ryan, PhD, University of Manchester, Manchester, UK, discusses the future of research into the NLRP3 inflammasome in frontotemporal dementia and Alzheimer’s disease. Areas of investigation include moving from in vitro to in vivo studies and repurposing NLRP3-targeted drugs, such as mefenamic acid, which are already approved for use in other diseases. This interview took place at the Alzheimer’s Research UK Conference 2022 in Brighton, UK.